Natural killer cell-mediated cytotoxicity enhancement

Natural killer (NK) cell-mediated cytotoxicity enhancement refers to a range of strategies designed to boost the innate immune function of NK cells, which recognize and destroy tumor cells or virally infected cells without prior antigen sensitization. Approaches include cytokine treatment (such as IL-2, IL-15, IL-12, IL-18, and IL-21), monoclonal antibodies that mediate ADCC (e.g., rituximab, trastuzumab, cetuximab), checkpoint blockade antibodies (e.g., monalizumab targeting NKG2A), and the use of engineered NK cell engagers (such as trispecific killer engagers, TriKEs). The enhancement of NK cell cytotoxicity is a central aim in developing effective cancer immunotherapies, exploiting both cell-intrinsic pathways (e.g., Ca2+-dependent granule release and NFAT/calcineurin signaling) and extrinsic adjuvants. Because this is a cellular process rather than a molecule, it cannot be mapped to a single canonical target entity[1][2][4].

Other names

NK cell cytotoxicity enhancementEnhanced NK cell-mediated cytotoxicityAugmented NK cell cytotoxicity

Cytokine-mediated activation (through upregulation of receptors and cytolytic molecules)[4]; Monoclonal antibody-mediated antibody-dependent cellular cytotoxicity (ADCC)[4]; Checkpoint blockade of inhibitory receptors (e.g., NKG2A, PD-1)[4]; Direct engagement of activating receptors on NK cells[4]